At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
vorinostat +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating vorinostat, therapeutic conventional surgery, and 1 other intervention for Adult Giant Cell Glioblastoma and 3 related conditions. Completed, enrolled 44 participants across 214 sites.
Detailed Summary
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with progressive, recurrent glioblastoma multiforme. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartJul 2008
Primary CompletionJul 2010
Study CompletionNov 2010
TodayJul 2026
First PostedMar 24, 2008
Enrollment StartJul 1, 2008
Primary CompletionJul 1, 2010
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.3 years ago
Interventions
vorinostatdrug
Given orally
therapeutic conventional surgeryprocedure
Patient undergoes surgery
bortezomibdrug
Given IV